DioseveはiPS細胞由来の卵子作成技術の開発と不妊治療等への応用を目指します。
Total raised: $7M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.07.2024 | - | $7M | - |
Mentions in press and media 5
| Date | Title | Description |
| 12.07.2024 | Dioseve Inc. Raises $7 Million in Funding Round | Dioseve Inc., a Tokyo-based company focused on assisted reproductive technology, has successfully raised $7 million in a recent funding round. The funding, led by Spiral Capital and Archetype Ventures, will be used to further research and d... |
| 09.07.2024 | Dioseve Completes USD7M Funding | Dioseve Inc., a Tokyo, Japan-based developer of assisted reproductive technology using oocytes derived from iPS cells, raised USD7m in funding. Backers included Spiral Capital, Archetype Ventures, ANRI, ASKA Pharmaceutical Co., DG Daiwa Ven... |
| 27.06.2024 | Dioseve Completes Funding Round, Raising a Total of 7 Million USD | TOKYO, June 27, 2024 /PRNewswire/ -- Dioseve Inc. (Headquarters: Tokyo; CEO: Kazuma Kishida; hereinafter "the Company"), aiming to develop assisted reproductive technology using oocytes derived from iPS cells, has raised 7 million... |
| 22.08.2022 | Dioseve wants to help infertile people with tech that grows egg cells | Based in Japan, biotech startup Dioseve’s ambitious goal is to grow human oocytes, or eggs, from other tissue. Its aim is to help people struggling with infertility, and it recently raised $3 million led by ANRI, with participation from Cor... |
| - | Dioseve | “Dioseve aims to develop IPS cell-derived egg production technology and apply it to infertility treatment, etc.” |